% | $
Quotes you view appear here for quick access.

Puma Biotechnology, Inc. Message Board

  • doc_3377 doc_3377 Feb 6, 2014 7:52 PM Flag

    Good outcome of patent situation in Europe!!

    Here's the link

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The patent (EP 1848414) includes the claim "for the pharmaceutical composition comprising an irreversible EGFR inhibitor for use in treating cancer in a subject having a T790M mutation". Boehringer Ingelheim's marketed drug, afatinib (Gilotrif ), is being sold or this use, It would seem that BI is now infringing the Puma patent and would need to obtain a license and pay royalties to continue to sell this drug.

      Sentiment: Strong Buy

49.89+1.37(+2.82%)Jul 29 4:01 PMEDT